CA
PTGX icon

Cliff Asness’s Protagonist Therapeutics PTGX Stock Holding History

Cliff Asness’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Buy
13,096
+1,222
+10% +$128K ﹤0.01% 2754
2026
Q1 		$1.25M Buy
11,874
+4,920
+71% +$436K ﹤0.01% 2643
2025
Q4 		$607K Sell
6,954
-1,616
-19% -$132K ﹤0.01% 2812
2025
Q3 		$569K Sell
8,570
-8,839
-51% -$502K ﹤0.01% 2753
2025
Q2 		$962K Sell
17,409
-22,678
-57% -$1.09M ﹤0.01% 2227
2025
Q1 		$1.94M Sell
40,087
-110,010
-73% -$4.61M ﹤0.01% 1627
2024
Q4 		$5.79M Buy
150,097
+12,926
+9% +$564K 0.01% 1038
2024
Q3 		$6.17M Buy
137,171
+112,116
+447% +$4.53M 0.01% 963
2024
Q2 		$868K Sell
25,055
-55,952
-69% -$1.64M ﹤0.01% 1818
2024
Q1 		$2.34M Buy
81,007
+71,665
+767% +$1.95M ﹤0.01% 1343
2023
Q4 		$214K Sell
9,342
-1,124
-11% -$19.7K ﹤0.01% 2191
2023
Q3 		$175K Sell
10,466
-653
-6% -$12.7K ﹤0.01% 2161
2023
Q2 		$307K Buy
+11,119
New +$278K ﹤0.01% 1929
2023
Q1 		– Sell
-40,970
Closed -$447K – 2236
2022
Q4 		$447K Sell
40,970
-73,718
-64% -$622K ﹤0.01% 1850
2022
Q3 		$967K Buy
+114,688
New +$1.09M ﹤0.01% 1533
2022
Q1 		– Sell
-15,177
Closed -$519K – 2280
2021
Q4 		$519K Sell
15,177
-26,500
-64% -$838K ﹤0.01% 1812
2021
Q3 		$739K Buy
41,677
+15,069
+57% +$642K ﹤0.01% 1703
2021
Q2 		$1.19M Sell
26,608
-3,779
-12% -$125K ﹤0.01% 1504
2021
Q1 		$787K Buy
30,387
+6,964
+30% +$176K ﹤0.01% 1656
2020
Q4 		$472K Buy
23,423
+623
+3% +$13.4K ﹤0.01% 1812
2020
Q3 		$446K Buy
+22,800
New +$428K ﹤0.01% 1780
2020
Q2 		– Sell
-11,347
Closed -$80K – 2150
2020
Q1 		$80K Sell
11,347
-11,340
-50% -$85K ﹤0.01% 1988
2019
Q4 		$160K Hold
22,687
– – ﹤0.01% 2038
2019
Q3 		$272K Buy
+22,687
New +$286K ﹤0.01% 1936

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cliff Asness's PTGX Position: Q2 2026 in Review

Cliff Asness increased its Protagonist Therapeutics (PTGX) stake by 10% in Q2 2026, buying an estimated $128K and bringing the position to 13,096 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

Cliff Asness first reported a position in PTGX in Q3 2019 and has held it in 24 quarters since. The position peaked at $6.17M in Q3 2024. 341 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Cliff Asness held 13,096 shares of Protagonist Therapeutics worth $1.61M as of Q2 2026.
  • Cliff Asness bought 1,222 Protagonist Therapeutics shares in Q2 2026, an estimated $128K.
  • Protagonist Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2754 holding.
  • Cliff Asness first reported a position in Protagonist Therapeutics in Q3 2019 and has held it in 24 quarters since.
  • Cliff Asness's Protagonist Therapeutics position peaked at $6.17M in Q3 2024.
  • 341 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.